3 Tyres Maker, Two Wheeler Lighting and Mirrors Maker and Pharmaceutical Company Stocks With a Strong Future Roadmap: Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals

Tyre, two wheeler parts and pharma stocks let investors follow companies that serve a growing part of the Indian economy. Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals cover a tyres maker, a two wheeler lighting and mirrors maker and a pharmaceutical company.

This list covers three tyre, two wheeler parts and pharma stocks with complete current figures: Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Tyre, Two Wheeler Parts and Pharma Stocks?

Tyre, two wheeler parts and pharma stocks are listed companies that make tyres for cars, trucks and farm vehicles, produce lighting, mirrors and signalling parts for two wheelers and cars, and develop and sell branded and generic medicines. Their earnings depend on replacement tyre sales, vehicle output and prescription demand.

Tyre, Two Wheeler Parts and Pharma Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing tyre, two wheeler parts and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in tyre, two wheeler parts and pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Tyre, Two Wheeler Parts and Pharma Stocks Have a Strong Roadmap in India?

Tyre, two wheeler parts and pharma stocks have a strong roadmap in India because a rising vehicle base, strong two wheeler production and steady demand for quality medicines keep widening the market for these companies.

• Tyres. More vehicles on the road need more tyres.
• Lighting and mirrors. Two wheelers need many safety parts.
• Pharma. Branded medicines reach more markets.

Why Apollo Tyres Features Among These Tyre, Two Wheeler Parts and Pharma Stocks

Among the tyre, two wheeler parts and pharma stocks on this list, Apollo Tyres is an Indian tyre maker with plants in India and Europe that sells passenger car, truck and bus, two-wheeler, farm and off-highway tyres under the Apollo and Vredestein brands.

In the June 2026 quarter, revenue grew 13.3% year on year to Rs 7,456 crore. Revenue rose from Rs 21,071 crore in FY22 to Rs 28,604 crore in FY26, a compound annual growth rate of 7.9%.

Net profit grew from Rs 639 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 21.1%. The company has a return on equity of 12.4%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 24,413 crore. The stock trades at a P/E of 14.3, below the industry P/E of 19.2.

Roadmap: The company is growing its premium and radial offerings and using its European presence to serve global customers. A strong dealer network in India supports replacement sales.

What to watch: Follow raw material costs, replacement demand and the performance of the European business.

Why Fiem Industries Features Among These Tyre, Two Wheeler Parts and Pharma Stocks

Among the rubber wheel, mirror and medicine shares on this list, Fiem Industries makes automotive lighting, signalling equipment and rear view mirrors, mainly for two-wheelers, with leading Japanese and Indian makers as customers.

The company has a return on equity of 21.0%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 4,790 crore. The stock trades at a P/E of 18.2, below the industry P/E of 36.9.

Revenue rose from Rs 1,575 crore in FY22 to Rs 2,836 crore in FY26, a compound annual growth rate of 15.8%. Net profit grew from Rs 95.3 crore in FY22 to Rs 256 crore in FY26, which works out to a compound annual growth rate of 28.0%. In the June 2026 quarter, revenue grew 17.4% year on year to Rs 780 crore, while net profit rose 12.9% to Rs 64.9 crore.

Roadmap: LED lighting is replacing older bulbs, which raises the value of each vehicle's lighting set. Fiem is also adding capacity and customers, and the move to premium two-wheelers helps its mix.

What to watch: Follow two-wheeler production volumes and customer-specific launch schedules.

Why Glenmark Pharmaceuticals Features Among These Tyre, Two Wheeler Parts and Pharma Stocks

Among the three companies on this list, Glenmark Pharmaceuticals is a research-driven pharma company with branded generics in India and other emerging markets, generics in the United States and Europe, and an innovation arm focused on new drugs.

Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%.

In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7.

Roadmap: The company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What to watch: Track new product launches, progress in the innovation pipeline and balance sheet strength.

Apollo Tyres vs Fiem Industries vs Glenmark Pharmaceuticals on Key Financials

The table below sets the three tyre, two wheeler parts and pharma stocks side by side on revenue, profit and margin, using reported figures.

Glenmark Pharmaceuticals posts the highest return on equity in this group at 28.1%. Apollo Tyres has the largest FY26 revenue at Rs 28,604 crore, and Fiem Industries shows the fastest revenue growth with a 15.8% compound annual rate. A useful habit with tyre, two wheeler parts and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Tyre, Two Wheeler Parts and Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these tyre, two wheeler parts and pharma stocks, the main points are: Long-term rubber wheel, mirror and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Rubber and carbon black costs. Raw material prices can move margins.
• Production cycles. Vehicle output can vary with demand.
• Pricing pressure. Generic prices can change by market.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter tyre, two wheeler parts and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Tyre, Two Wheeler Parts and Pharma Stocks

Tyre, two wheeler parts and pharma stocks reward investors who follow demand trends, order books and margins together. Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals each have a clear plan to grow. Based on the 11 November 2026 close, Apollo Tyres trades at Rs 423.85, Fiem Industries at Rs 1,932.9 and Glenmark Pharmaceuticals at Rs 2,677.2. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these tyre, two wheeler parts and pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track tyre, two wheeler parts and pharma stocks, set price alerts and get research-backed stock ideas.

What are tyre, two wheeler parts and pharma stocks?

Ans. Tyre, two wheeler parts and pharma stocks are listed companies that make tyres for cars, trucks and farm vehicles, produce lighting, mirrors and signalling parts for two wheelers and cars, and develop and sell branded and generic medicines. Their earnings depend on replacement tyre sales, vehicle output and prescription demand. This list looks at three of them, Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which tyre, two wheeler parts and pharma stocks are covered in this list?

Ans. This list covers Apollo Tyres, Fiem Industries and Glenmark Pharmaceuticals. Based on the 11 November 2026 close, Apollo Tyres traded at Rs 423.85, Fiem Industries at Rs 1,932.9 and Glenmark Pharmaceuticals at Rs 2,677.2. Their return on equity ranges from 12.4% to 28.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 15.8%.

Why do tyre, two wheeler parts and pharma stocks have a strong future roadmap in India?

Ans. Tyre, two wheeler parts and pharma stocks have a strong roadmap in India because a rising vehicle base, strong two wheeler production and steady demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Tyres. More vehicles on the road need more tyres. Lighting and mirrors. Two wheelers need many safety parts. Pharma. Branded medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Apollo Tyres performed financially?

Ans. Revenue rose from Rs 21,071 crore in FY22 to Rs 28,604 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 639 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 21.1%. In the June 2026 quarter, revenue grew 13.3% year on year to Rs 7,456 crore. The company has a return on equity of 12.4%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 24,413 crore. The stock trades at a P/E of 14.3, below the industry P/E of 19.2. Looking ahead, the company is growing its premium and radial offerings and using its European presence to serve global customers. A strong dealer network in India supports replacement sales.

How has Fiem Industries performed financially?

Ans. Revenue rose from Rs 1,575 crore in FY22 to Rs 2,836 crore in FY26, a compound annual growth rate of 15.8%. Net profit grew from Rs 95.3 crore in FY22 to Rs 256 crore in FY26, which works out to a compound annual growth rate of 28.0%. In the June 2026 quarter, revenue grew 17.4% year on year to Rs 780 crore, while net profit rose 12.9% to Rs 64.9 crore. The company has a return on equity of 21.0%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 4,790 crore. The stock trades at a P/E of 18.2, below the industry P/E of 36.9. Looking ahead, lED lighting is replacing older bulbs, which raises the value of each vehicle's lighting set. Fiem is also adding capacity and customers, and the move to premium two-wheelers helps its mix.

How has Glenmark Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 12,472 crore in FY22 to Rs 17,443 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 994 crore in FY22 to Rs 1,362 crore in FY26, which works out to a compound annual growth rate of 8.2%. In the June 2026 quarter, revenue grew 24.1% year on year to Rs 4,084 crore. The company has a return on equity of 28.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 60,103 crore. The stock trades at a P/E of 33.4, below the industry P/E of 35.7. Looking ahead, the company is strengthening its dermatology and respiratory franchises and advancing its innovation pipeline, which could add higher-value income. Growth in India and emerging markets supports steady sales.

What risks should investors check before buying tyre, two wheeler parts and pharma stocks?

Ans. Investors should check a few risks before buying tyre, two wheeler parts and pharma stocks. Rubber and carbon black costs. Raw material prices can move margins. Production cycles. Vehicle output can vary with demand. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of tyre, two wheeler parts and pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.